Active Smallcap & Microcap Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products
ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.
Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.
"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
$GTVH News: Golden Triangle Ventures Announces Four-Pillar Business Model for Lavish Entertainment
LAS VEGAS, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce that Lavish Entertainment (or “Lavish”), a wholly owned subsidiary of GTV, has developed a comprehensive four-pillar business model. This strategic framework is a critical component in advancing Lavish Entertainment’s mission to create an industry leading entertainment business.
Lavish Entertainment’s new model encompasses the following key foundational elements: logistics, staffing, equipment, and production. These pillars were meticulously identified and organized to complement each other and ensure seamless operations across all facets of the Company. To enhance its bandwidth and expand service offerings, Lavish Entertainment intends to develop and acquire operations in each of the four key areas.
Logistics: Effective logistics are the backbone of any successful entertainment operation. From coordinating event schedules to managing transportation and venue setup, logistical prowess ensures smooth operations and optimal audience experiences. By establishing a dedicated logistics business, Lavish Entertainment can streamline its event planning processes, ensure seamless coordination of resources and services, minimize delays, and enhance overall efficiency. The Company’s integrated logistics and expertise will be instrumental in orchestrating the complex movement of resources required for the development and ongoing operation of Lavish Entertainment and projects such as Destino Ranch.
Staffing: Talent and manpower are indispensable assets in the entertainment industry. Whether it's skilled technicians, event coordinators or guest services personnel, assembling the right team is essential for delivering memorable experiences. Lavish Entertainment's staffing division will focus on recruiting, training and managing a diverse array of talent to meet the demands of its multifaceted operations. By ensuring a well-trained and motivated workforce, Lavish Entertainment will elevate the quality of its services and cultivate a culture of excellence, which will be pivotal in providing exceptional guest experiences at its events.
Equipment: At the forefront of its corporate vision is cutting-edge equipment and state-of-the-art technology, which are indispensable for creating an immersive entertainment experience. From orchestral-quality sound systems to advanced lighting and visual effects equipment, investing in high-quality gear is essential for captivating audiences and delivering unforgettable moments. Lavish Entertainment's comprehensive strategy will focus on acquiring, maintaining and upgrading a vast equipment inventory to support a diverse range of productions and events. Top-tier equipment will allow Lavish Entertainment to push the boundaries of creativity and innovation, deliver memorable experiences, and leave forever lasting impressions.
Production: Whether it's designing captivating stage sets, crafting compelling narratives or executing seamless live performances, the art of production is paramount for success. The level of expertise in production makes the difference between uninspired and unforgettable. It is essential for bringing creative visions to life and is a critical pillar to advance Lavish Entertainment forward. From concerts and theatrical productions to immersive events and sensory spectacles, the Company will leverage the talents of seasoned professionals to conceptualize, plan and execute a diverse array of entertainment experiences. This commitment to production excellence will be driven by meticulously crafted details to provide the best events possible.
This business model will directly apply to Lavish’s flagship project, Destino Ranch (www.DestinoRanch.com). The auspicious project, one of Lavish’s largest undertakings, will be managed by the Company’s newest acquisition, ABI Create (www.ABIcreate.com), a premier event management and production firm. ABI will maximize the integrated synergy of these four pillars to amplify the development of Destino Ranch and will utilize the project to showcase the newly formed strategic model.
“We are thrilled to introduce our innovative four-pillar business model, which represents a bold step forward in our journey to develop Lavish Entertainment into a staple in the entertainment industry,” said Marco Antonio Moreno, president and COO at Lavish Entertainment. “We look forward to showing our shareholders how this new business model will unfold.”
Learn More
www.DestinoRanch.com
www.ABICreate.com.
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the business that management believes it can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long-term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
For more information, visit us at: www.GoldenTriangleInc.com
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high-quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment is currently developing a flagship entertainment complex called Destino Ranch, which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The Company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project, which is strategically located in Arizona. The property has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Lavish Entertainment has completed a full acquisition of ABI Create (or “ABI”), a premier event management and production firm, which is managing the development of its Destino Ranch project. Founded in 2015 by Marco Antonio Moreno (recently appointed as the new president and COO of Lavish Entertainment), ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States. Notable projects include collaborations with the NFL Super Bowl, San Diego and New York Comic Con, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man, and many more.
Forward-Looking Statements
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: www.twitter.com/GTV_Inc
CONTACT INFORMATION:
Golden Triangle Ventures, Inc.
info@GoldenTriangleInc.com
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$GTVH News: Golden Triangle Ventures Announces Four-Pillar Business Model for Lavish Entertainment
LAS VEGAS, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce that Lavish Entertainment (or “Lavish”), a wholly owned subsidiary of GTV, has developed a comprehensive four-pillar business model. This strategic framework is a critical component in advancing Lavish Entertainment’s mission to create an industry leading entertainment business.
Lavish Entertainment’s new model encompasses the following key foundational elements: logistics, staffing, equipment, and production. These pillars were meticulously identified and organized to complement each other and ensure seamless operations across all facets of the Company. To enhance its bandwidth and expand service offerings, Lavish Entertainment intends to develop and acquire operations in each of the four key areas.
Logistics: Effective logistics are the backbone of any successful entertainment operation. From coordinating event schedules to managing transportation and venue setup, logistical prowess ensures smooth operations and optimal audience experiences. By establishing a dedicated logistics business, Lavish Entertainment can streamline its event planning processes, ensure seamless coordination of resources and services, minimize delays, and enhance overall efficiency. The Company’s integrated logistics and expertise will be instrumental in orchestrating the complex movement of resources required for the development and ongoing operation of Lavish Entertainment and projects such as Destino Ranch.
Staffing: Talent and manpower are indispensable assets in the entertainment industry. Whether it's skilled technicians, event coordinators or guest services personnel, assembling the right team is essential for delivering memorable experiences. Lavish Entertainment's staffing division will focus on recruiting, training and managing a diverse array of talent to meet the demands of its multifaceted operations. By ensuring a well-trained and motivated workforce, Lavish Entertainment will elevate the quality of its services and cultivate a culture of excellence, which will be pivotal in providing exceptional guest experiences at its events.
Equipment: At the forefront of its corporate vision is cutting-edge equipment and state-of-the-art technology, which are indispensable for creating an immersive entertainment experience. From orchestral-quality sound systems to advanced lighting and visual effects equipment, investing in high-quality gear is essential for captivating audiences and delivering unforgettable moments. Lavish Entertainment's comprehensive strategy will focus on acquiring, maintaining and upgrading a vast equipment inventory to support a diverse range of productions and events. Top-tier equipment will allow Lavish Entertainment to push the boundaries of creativity and innovation, deliver memorable experiences, and leave forever lasting impressions.
Production: Whether it's designing captivating stage sets, crafting compelling narratives or executing seamless live performances, the art of production is paramount for success. The level of expertise in production makes the difference between uninspired and unforgettable. It is essential for bringing creative visions to life and is a critical pillar to advance Lavish Entertainment forward. From concerts and theatrical productions to immersive events and sensory spectacles, the Company will leverage the talents of seasoned professionals to conceptualize, plan and execute a diverse array of entertainment experiences. This commitment to production excellence will be driven by meticulously crafted details to provide the best events possible.
This business model will directly apply to Lavish’s flagship project, Destino Ranch (www.DestinoRanch.com). The auspicious project, one of Lavish’s largest undertakings, will be managed by the Company’s newest acquisition, ABI Create (www.ABIcreate.com), a premier event management and production firm. ABI will maximize the integrated synergy of these four pillars to amplify the development of Destino Ranch and will utilize the project to showcase the newly formed strategic model.
“We are thrilled to introduce our innovative four-pillar business model, which represents a bold step forward in our journey to develop Lavish Entertainment into a staple in the entertainment industry,” said Marco Antonio Moreno, president and COO at Lavish Entertainment. “We look forward to showing our shareholders how this new business model will unfold.”
Learn More
http://www.DestinoRanch.com
http://www.ABICreate.com.
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the business that management believes it can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long-term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
For more information, visit us at: http://www.GoldenTriangleInc.com
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high-quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment is currently developing a flagship entertainment complex called Destino Ranch, which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The Company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project, which is strategically located in Arizona. The property has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Lavish Entertainment has completed a full acquisition of ABI Create (or “ABI”), a premier event management and production firm, which is managing the development of its Destino Ranch project. Founded in 2015 by Marco Antonio Moreno (recently appointed as the new president and COO of Lavish Entertainment), ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States. Notable projects include collaborations with the NFL Super Bowl, San Diego and New York Comic Con, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man, and many more.
Forward-Looking Statements
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: www.twitter.com/GTV_Inc
CONTACT INFORMATION:
Golden Triangle Ventures, Inc.
info@GoldenTriangleInc.com
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDIyNSM2MjEzNzA2IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ODIwZWYyMTctYWIzMi00MmZiLTk5ZjctMjQ0YTEwMDUxMGMwLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDIyNSM2MjEzNzA2IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ODIwZWYyMTctYWIzMi00MmZiLTk5ZjctMjQ0YTEwMDUxMGMwLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
IVDN is on track for a record sales and revenue growth year, as clearly detailed in the official news we have seen recently. The nationwide distributor network that IVDN management has carefully assembled is meeting with accelerating success as word is spreading about the patented and unique Insultex House Wrap which outperforms all competitive products by a wide margin. Add to this advantage, the fact that the IVDN product meets or exceeds new building codes going into effect this year requiring continuous insulation while competitors are failing this critical criteria.
Real IVDN investors, who understand the full picture developing here, and who have a mature, patient attitude, are set up for high rewards when we see the upcoming financial results for the balance of this year.
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
$GDHG -Join us on our journey where every milestone is a testament to our unwavering dedication to creating unforgettable experiences for millions. Together, let's chart a course towards a future filled with growth, profitability, and boundless excitement. https://ir.jsyoule.com
$GDHG -Join us on our journey where every milestone is a testament to our unwavering dedication to creating unforgettable experiences for millions. Together, let's chart a course towards a future filled with growth, profitability, and boundless excitement. https://t.co/o6KKIHgysk pic.twitter.com/1zmNWRmtJN
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 23, 2024
$GDHG -Join us on our journey where every milestone is a testament to our unwavering dedication to creating unforgettable experiences for millions. Together, let's chart a course towards a future filled with growth, profitability, and boundless excitement. https://ir.jsyoule.com
$GDHG -Join us on our journey where every milestone is a testament to our unwavering dedication to creating unforgettable experiences for millions. Together, let's chart a course towards a future filled with growth, profitability, and boundless excitement. https://t.co/o6KKIHgysk pic.twitter.com/1zmNWRmtJN
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 23, 2024
$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/
Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.
Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.
Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.
Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.
Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.
Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.
$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below:
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
NCL is forward looking company that is making excellent professional alliances to grow its business on a global sale. The NCL technology to deliver sustainable building products made from recycled ocean plastics is also a valuable contribution to the health of the planet for decades to come.
From today's news:
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
$GMPR Update: Unique Global Innovative Solutions Corp@Unique_Global_
Aerosolization can decontaminate the water that is buried in deep injection wells! Founder of Aerosolization (by exclusive invite) was in NC last week and MI this week doing demos for the DoD #DrillBabyDrill #FrackBabyFrack & because of AerosoliZLD™ do it #CleanBabyClean $GMPR
https://twitter.com/Unique_Global_/status/1783129689877270694
$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products
ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.
Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.
"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDg4NiM2MjE2NTUyIzIyNTM4NDA=
https://ml.globenewswire.com/media/MjQ2NTdjZDQtMDFkMS00NjI4LWE0MTEtZDZkOTEzYjA1ZDkzLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products
ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.
Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.
"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTEwNDg4NiM2MjE2NTUyIzIyNTM4NDA=
https://ml.globenewswire.com/media/MjQ2NTdjZDQtMDFkMS00NjI4LWE0MTEtZDZkOTEzYjA1ZDkzLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$MNTS and $ASTI Partnership: Momentus and Ascent Solar Technologies Partner to Bring Leading-Edge Solar Arrays to Market
Innovative solar arrays to address burgeoning demand
SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable and high performing solar arrays. Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers such as lower costs, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.
Building off the successes of the pathfinder demonstration of TASSA that was launched to Low-Earth Orbit on the Vigoride-6 mission one year ago and tested in space for several months, Momentus plans to add a high-power photovoltaic array as a differentiated feature of the next iteration of the TASSA product under development. Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent, as a mass efficient and robust power generation solution. Momentus plans to incorporate in TASSA new higher efficiency solar blankets from Ascent composed of space industry optimized Titan Modules, achieving even lower cost per kW of power.
TASSA will continue to utilize Vigoride hardware with spaceflight heritage to provide customers an entire array subsystem, complete with solar array rotation actuators and controllers. This approach is oriented at streamlining mission schedules and minimizing clean room bottlenecks during spacecraft assembly integration and testing. TASSA is designed for responsive launch as well as more efficient flatpack configurations which allow for more satellites to fit within launch vehicle payload fairings.
“TASSA is designed to generate extensive power at very low cost while minimizing mass and volume,” said Rob Schwarz, Momentus CTO. “TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper.”
TASSA is also retractable and re-deployable providing a means for the minimization of cross-sectional area and array exposure if notified of potential conjunction or other orbital hazards such as space weather. This could enable TASSA to facilitate longer mission durations and increased assurance of spacecraft operations on orbit.
“Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment,” said Paul Warley, CEO of Ascent Solar Technologies. “Our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA, and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures.”
ABOUT MOMENTUS
Momentus is a U.S. commercial space company that offers satellite buses and technologies, as well as space services including transportation, hosted payloads, and other in-orbit services.
ABOUT ASCENT SOLAR TECHNOLOGIES, INC.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com or follow the Company on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
This press release contains certain statements which may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words “may,” “will,” “anticipate,” “believe,” “expect,” “continue,” “could,” “estimate,” “future,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “aim,” “strive,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to generate revenue and raise capital in order to continue as a going concern; the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the U.S. Securities and Exchange Commission including, but not limited to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s filings may be accessed through the Investor Relations page of its website, investors.momentus.space, or through the website maintained by the SEC at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
MEDIA CONTACT
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
INVESTOR RELATIONS CONTACT
ir@ascentsolar.com
https://www.globenewswire.com/newsroom/ti?nf=OTA5MDY1OSM2MjA0NDU2IzUwMDExNDU4Mw==
https://ml.globenewswire.com/media/NWI4MGQxZTUtZDM5My00M2QwLWEzNjAtYjFiM2Q2NTVkYmUzLTUwMDExNDU4Mw==/tiny/Ascent-Solar-Technologies-Inc-.png
Source: Ascent Solar Technologies, Inc.
The two very capable, high-tech companies of ASTI and MNTS should be able to work extremely well together and jointly contribute to the success of vital aerospace projects like the TASSA missions now underway. This looks like a perfect match-up.
From the news:
"Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment," says Paul Warley, ASTI CEO, "as our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures."
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://goldenheavengroup.gcs-web.com/news-releases/news-release-details/golden-heaven-group-holdings-ltd-expand-indonesia-market-its… $DIS $SEAS $SIX $FUN $CMCSA
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://t.co/orjysKZ7Pm $DIS $SEAS $SIX $FUN $CMCSA pic.twitter.com/NX40gcWqPy
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 23, 2024
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://goldenheavengroup.gcs-web.com/news-releases/news-release-details/golden-heaven-group-holdings-ltd-expand-indonesia-market-its… $DIS $SEAS $SIX $FUN $CMCSA
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://t.co/orjysKZ7Pm $DIS $SEAS $SIX $FUN $CMCSA pic.twitter.com/NX40gcWqPy
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 23, 2024
$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$RENB: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTA5MTc2OSM2MjA3NjI3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/YjM1MjkzZDUtZGE5Yi00MjI0LWI5M2MtMjcxMGI0YThiNzk1LTExMzIyNTA=/tiny/Renovaro-Biosciences-Inc-.png
Source: Renovaro Biosciences Inc.
$RENB: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTA5MTc2OSM2MjA3NjI3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/YjM1MjkzZDUtZGE5Yi00MjI0LWI5M2MtMjcxMGI0YThiNzk1LTExMzIyNTA=/tiny/Renovaro-Biosciences-Inc-.png
Source: Renovaro Biosciences Inc.
$NCL News: Northann Corp Announces Cross-Licensing Agreement with I4F for Digital Printing Technology
ELK GROVE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce a strategic cross-licensing agreement with I4F, a group of companies providing patents and technologies to the flooring industry.
This agreement solidifies a collaborative effort between the two companies to enhance their respective offerings in the digital printing space. Northann Corp's commitment to innovation and quality aligns perfectly with I4F's expertise in digital printing technology, creating a synergy that promises exciting advancements in the flooring industry.
"Intellectual property should not be a barrier to technological and industry advancements; it should be a catalyst for continuous innovation for humanity and the industry as a whole," said Lin Li, CEO of Northann Corp. "Our cross-license agreement with I4F is designed to further democratize this technology and help I4F's digital printing licensees greatly reduce manufacturing costs and entry barriers. After this cross-license agreement, Northann Corp will manufacture its 3D printing ecosystem with digital printing production lines in the United States, drastically reducing production costs, and further solidifying Northann’s foothold within the industry."
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTA4NzE5NCM2MTk0NzA4IzIyNTM4NDA=
https://ml.globenewswire.com/media/Njk0MWU2ZDMtZGE3Yy00OWQ4LWIzZmQtZjE3NTg1ZDA3MTZiLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$GVH Experienced, Well Partnered, Effortless and Debt Free e-Commerce Logistics Provider Serving the Lucrative Asia- Pacific Market: Globavend Holdings Limited (Nasdaq: GVH)
https://www.benzinga.com/pressreleases/24/03/ab37795054/experienced-well-partnered-effortless-and-debt-free-e-commerce-logistics-provider-serving-the-luc
$GVH Experienced, Well Partnered, Effortless and Debt Free e-Commerce Logistics Provider Serving the Lucrative Asia- Pacific Market: Globavend Holdings Limited (Nasdaq: GVH)
https://www.benzinga.com/pressreleases/24/03/ab37795054/experienced-well-partnered-effortless-and-debt-free-e-commerce-logistics-provider-serving-the-luc
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
Buying continues to come into AVRW to kick off a new week. The stock pps is responding nicely with a walking up getting underway, as we can see with a move into the .05 level already. Investors are seeing how oversold this stock is right now and accumulating in anticipation of the very positive sales growth year projected for 2024.
Randy Kimbler is part of the nationwide IVDN distributor network which is now growing with the addition of many new vendors due to the increasing awareness of Insultex in the building and construction market place.
A listing of this network appears on the IVDN website here:
Retailers/Distributors/Contractors/Homebuilders/Etc. that have purchased Insultex™ House Wrap®
https://insultexhousewrap.com/users/
---------------------------------------------------------------------------------------------------------------------------------------
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$ITMC management has just filed the company's 10K Annual Report for the year ending on December 31st. This is the most expensive financial report of the year to complete so seeing it filed now is a good indicator that the company will have some new business developments for the future. Hopefully, we will start to have new announcements starting up here again soon.
10K Filing Link:
https://www.otcmarkets.com/otcapi/company/financial-report/398189/content
$MNTS and $ASTI Partnership: Momentus and Ascent Solar Technologies Partner to Bring Leading-Edge Solar Arrays to Market
Innovative solar arrays to address burgeoning demand
SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable and high performing solar arrays. Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers such as lower costs, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.
Building off the successes of the pathfinder demonstration of TASSA that was launched to Low-Earth Orbit on the Vigoride-6 mission one year ago and tested in space for several months, Momentus plans to add a high-power photovoltaic array as a differentiated feature of the next iteration of the TASSA product under development. Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent, as a mass efficient and robust power generation solution. Momentus plans to incorporate in TASSA new higher efficiency solar blankets from Ascent composed of space industry optimized Titan Modules, achieving even lower cost per kW of power.
TASSA will continue to utilize Vigoride hardware with spaceflight heritage to provide customers an entire array subsystem, complete with solar array rotation actuators and controllers. This approach is oriented at streamlining mission schedules and minimizing clean room bottlenecks during spacecraft assembly integration and testing. TASSA is designed for responsive launch as well as more efficient flatpack configurations which allow for more satellites to fit within launch vehicle payload fairings.
“TASSA is designed to generate extensive power at very low cost while minimizing mass and volume,” said Rob Schwarz, Momentus CTO. “TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper.”
TASSA is also retractable and re-deployable providing a means for the minimization of cross-sectional area and array exposure if notified of potential conjunction or other orbital hazards such as space weather. This could enable TASSA to facilitate longer mission durations and increased assurance of spacecraft operations on orbit.
“Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment,” said Paul Warley, CEO of Ascent Solar Technologies. “Our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA, and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures.”
ABOUT MOMENTUS
Momentus is a U.S. commercial space company that offers satellite buses and technologies, as well as space services including transportation, hosted payloads, and other in-orbit services.
ABOUT ASCENT SOLAR TECHNOLOGIES, INC.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com or follow the Company on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
This press release contains certain statements which may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words “may,” “will,” “anticipate,” “believe,” “expect,” “continue,” “could,” “estimate,” “future,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “aim,” “strive,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to generate revenue and raise capital in order to continue as a going concern; the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the U.S. Securities and Exchange Commission including, but not limited to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s filings may be accessed through the Investor Relations page of its website, investors.momentus.space, or through the website maintained by the SEC at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
MEDIA CONTACT
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
INVESTOR RELATIONS CONTACT
ir@ascentsolar.com
https://www.globenewswire.com/newsroom/ti?nf=OTA5MDY1OSM2MjA0NDU2IzUwMDExNDU4Mw==
https://ml.globenewswire.com/media/NWI4MGQxZTUtZDM5My00M2QwLWEzNjAtYjFiM2Q2NTVkYmUzLTUwMDExNDU4Mw==/tiny/Ascent-Solar-Technologies-Inc-.png
Source: Ascent Solar Technologies, Inc.
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html